羟苯磺酸钙联合尿毒清颗粒治疗IgA肾病的临床观察

Clinical Observation of Calcium Dobesilate Combined with Niaoduqing Granules in the Treatment of IgA Nephropathy

目的:观察羟苯磺酸钙胶囊联合尿毒清颗粒治疗免疫球蛋白A(IgA)肾病的临床疗效。方法:将82例IgA肾病患者随机均分为对照组和治疗组。对照组在常规治疗的基础上加用尿毒清颗粒,治疗组在对照组的基础上加用羟苯磺酸钙。2组疗程均为3个月。观察2组的治疗效果,检测2组治疗前后血纤维蛋白原(FIB)、尿素氮(BUN)、血清肌酐(Scr)、血尿酸(UA)、内生肌酐清除率(Ccr)、24小时尿蛋白定量等变化情况和不良反应。结果:治疗后,治疗组FIB水平明显低于治疗前,且与对照组比较,差异有统计学意义(P<0.05);2组均能显著降低Scr、UA、24小时尿蛋白定量(P<0.05或P<0.01);治疗组Ccr治疗后明显上升,且与对照组比较,差异有统计学意义(P<0.05)。对照组未见不良反应,治疗组仅有2例轻微不良反应。结论:羟苯磺酸钙联合尿毒清颗粒治疗IgA肾病疗效确切。

OBJECTIVE： To observe the clinical efficacy of Calcium dobesilate capsule combined with Niaoduqing granules in the treatment of IgA nephropathy. METHODS ： 82 patients with IgA nephropathy were randomly divided into control group and treatment group. Control group was given Niaoduqing granules on the basis of conventional treatment, and treatment group was additionally given calcium dobesilate based on treatment of control group. After 3 months of treatment, therapeutic efficacies of 2 groups were observed. Changes of FIB, BUN, Scr, UA, Ccr and 24-h urine protein and adverse drug reactions in 2 groups were observed before and after treatment. RESULTS： After treatment, FIB level in treatment group was lower than before significantly, there was statistical significance （P〈0.05）. Scr, UA and 24-h urine protein in 2 groups were decreased significantly （P〈0.05 or P〈0.01）. Ccr in treatment group was significantly increased after treatment, there was statistical significance between 2 group （P〈0.05）. No adverse drug reaction was found in control group, while 2 cases of mild adverse drug reaction were observed in control group. CONCLUSION： Calcium dobesilate combined with Niaoduqing granule is effective in the treatment of IgA nephropathy.